Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.

Gabriella De Rosa, Maria Pia De Carolis, Iliana Bersani, Francesco Cota, Costantino Romagnoli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤ 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.
Lingua originaleEnglish
pagine (da-a)47-49
Numero di pagine3
RivistaIndian Pediatrics
Stato di pubblicazionePubblicato - 2012

Keywords

  • prophylaxis of patent ductus

Fingerprint

Entra nei temi di ricerca di 'Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.'. Insieme formano una fingerprint unica.

Cita questo